VivoSeq
Musculoskeletal

Osteoarthritis

528

Pipeline Programs↗

176

Active Trials↗

161

Companies Involved↗

Osteoarthritis is a highly competitive landscape with 528 programs across 161 companies. The most active players are Stryker Biotech, CAR-T (Shanghai) Biotechnology Co., Ltd., Unity Biotechnology, Inc.. 99 therapies are approved with 121 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

96/100

Pipeline Velocity

70/100

Mech. Concentration

14/100

Completion Rate

86/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Stryker Biotech

2 programs

Phase 1C

CAR-T (Shanghai) Biotechnology Co., Ltd.

2 programs

Phase 1U

Unity Biotechnology, Inc.

1 program

Phase 1E

Eupraxia Pharmaceuticals Inc.

1 program

Phase 1A

Avidence Therapeutics

1 program

Phase 1X

Xgene Pharmaceutical Group

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

92%

Small molecule

590 of 643 classified programs — the dominant modality here.

8%ALL OTHERSCell therapy345%Monoclonal antibody102%Peptide5<1%Protein / enzyme4<1%

Small molecule leads; the ring shows all 643 classified programs, each share of the total. Modality classified for 100% of 779 pipeline programs.

Analysis

Trial Status

1,046

clinical trials

Completed638 · 61%
Unknown status128 · 12%
Recruiting93 · 9%
Terminated68 · 7%
Not yet recruiting46 · 4%
Withdrawn35 · 3%
Other38 · 4%

Clinical Trials

Trial Activity

1046 trials

The Safety/Efficacy of hUC Mesenchymal Stem Cells（19#iSCLife®-OA） Therapy for Patients With Osteoarthritis
Recruiting·SSclnow Biotechnology Co., Ltd.·Phase 2·NCT03383081·60 enrolled
Metformin Safety and Efficacy in Osteoarthritis.
Recruiting·—·Phase 3·NCT06231758·70 enrolled
The Combined Use of PRP with Lipoaspirate And/or Bone Marrow Aspirate in Osteoarthritis
Recruiting·—·Phase 2·NCT03984461·240 enrolled
Sustained Acoustic Medicine for Osteoarthritis Pain
Recruiting·ZZetrOZ, Inc.·Phase 1·NCT05254574·200 enrolled
Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis
Recruiting·KKeyBioscience AG·Phase 2·NCT06833749·600 enrolled
Arthrosemid vs. Steroid for the Management Knee Osteoarthritis
Recruiting·—·Phase 4·NCT07489521·200 enrolled
Effect of Platelet-rich Plasma (PRP) Injection on Knee Osteoarthritis
Recruiting·XXijing Hospital·N/A·NCT06082531·300 enrolled
Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)
Recruiting·UUniversity of Melbourne·Phase 4·NCT06191848·352 enrolled
An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint
Recruiting·AAgeless Biotech, Inc.·Phase 2·NCT06485843·400 enrolled
Effect of Genicular Arteries Embolization in Symptomatic Knee Osteoarthritis LipioJoint-2
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT06497140·130 enrolled
The Effects of Patient and Visit Characteristics on Health Outcomes in Knee Osteoarthritis
Recruiting·UUniversity of California, Davis·N/A·NCT06574191·220 enrolled
Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of STT Osteoarthritis
Recruiting·TTBF Genie Tissulaire·Phase 2·NCT06038331·14 enrolled
Capsaicin in Digital Osteoarthritis Versus Control
Recruiting·UUniversity Hospital, Clermont-Ferrand·Phase 4·NCT06444919·120 enrolled
Biologic Therapy to Prevent Osteoarthritis After ACL Injury
Recruiting·UUniversity of California, Los Angeles·Phase 1·NCT03968913·32 enrolled
Intra-articular Allocetra in Osteoarthritis of the of the Temporomandibular Joint (TMJ)
Recruiting·—·Phase 1·NCT06748651·6 enrolled
Page 1 of 70

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)